UCHL1, Recombinant, Human (Ubiquitin Carboxyl-terminal Hydrolase Isozyme L1, UCH-L1, Neuron Cytoplasmic Protein 9.5, PGP 9.5, PGP9.5, Ubiquitin Thioesterase L1)

Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a deubiqutinating enzyme. Ubiquitin UCHL1, also known as PGP9.5, is a protein of 223aa and one of the most abundant proteins in the brain (1~2% of the total soluble protein). Although it was originally characterized as a deubiquitinating enzyme recent studies indicate that it also functions as a ubiquitin (Ub) ligase and a mono-Ub stabilizer. A large amount of mono-Ub is tightly associated with UCHL1, inhibiting the degradation of mono-Ub in the brain. The precise regulation of UCHL1 is essential for neurons to survive and to maintain their proper function. UCHL1 is involved in the pathogenesis of Parkinson's disease (PD) and Alzheimer's disease (AD). Down-regulation and extensive oxidative modification of UCHL1 have been observed in the brains of AD patients as well as PD patients. A post-translational modification of UCHL1 that controls the function of UCHL1 is mono-ubiquitination. It occurs reversibly to a lysine residue near the active site of UCHL1.\n\nSource:\nRecombinant corresponding to aa1-223 with N-GST tag, from human UCHL1, expressed in E.coli.\n\nMolecular Weight:\n~51kD\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

U1005-01M

Size

100ug

Form

Supplied as a lyophilized powder from 50mM Tris, pH8.0, 10mM GSH. Reconstitute with sterile dH2O PBS.

Purity

~90% (SDS-PAGE)

References

1. Setsuie Rand Wada K, 2007, Neurochem Int. 51(2-4):105-111. 2. Gong B and Leznik E, 2007, Drug News Perspect. 20(6):365-370. 3. Betarbet R et al. 2005, Exp Neurol. 191 Suppl 1:S17-27.